1. 毕业设计（论文）的内容和要求

1. 实验目的叙述 2. 实验所用仪器相关叙述，及溶剂相关叙述 3. 了解方法学验证相关流程，包括如下内容： 3.1专属性（定位各溶剂位置） 3.2进样精密度 3.3线性 3.4检测限定量限 3.5回收率 3.6样品检测 4. 实验内容原始记录，包括： 4.1本实验目的及方案 4.2所用仪器型号，色谱条件 4.3所用溶剂配置过程 4.4具体操作过程 4.5图谱叙述

2. 参考文献

[1]那彦群, 叶章群, 孙颖浩, 等 . 中国泌尿外科疾病诊断治疗指南 [M]. 北京：人民卫生出版社 , 2014:245-266. [2]李宁忱, 宋毅, 丁强, 等 . 赛洛多辛治疗良性前列腺增生的随机 双盲安慰剂对照多中心III 期临床研究[J]. 中华泌尿外科杂志, 2013, 34(4): 305-309. [3] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society[J].Am J Obstet Gynecol, 2002, 187(1): 116-126. [4] Nickel J C, Mendez-Probst C E, Whelan T F, et al. 2010 Update: Guidelines for the management of benign prostatic hyperplasia[J]. Can Urol Assoc J, 2010, 4(5): 310-316. [5] Lepor H, Kazzazi A, Djavan B. α-blockers for benign prostatic hyperplasia: the new era[J]. Curr Opin Urol, 2012, 22(1): 7-15. [6] Guimaraes S, Moura D. Vascular adrenoceptors: an update[J]. Pharmacol Rev, 2001, 53(2): 319-356. [6] Moon K H, Song P H, Yang D Y, et al. Efficacy and safety of the selective α1A-Adrenoceptor blocker silodosin for severe lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, single-open-aabel, multicenter study in Korea[J]. Korean J Urol, 2014, 55(5): 335-340. [7] Michel M C. The pharmacological pro#64257;le of the α1A-adrenoceptor antagonist silodosin[J]. Eur Urol Suppl, 2010, 9(4): 486-490. [8] Roehrborn C G, Schwinn D A. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia[J]. J Urol, 2004,171(3): 1029-1035. [9] Morishima S, Suzuki F, Nishimune A, et al. Visualization and tissue distribution of α1L-adrenoceptor in human prostate by the fluorescently labeled ligand Alexa-488-silodosin[J]. J Urol, 2010, 183(2): 812-819. [10] Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective α1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia[J]. Expert Opin Investig Drugs, 2007,16(12): 1955-1965. [11] Kawabe K, Yoshida M, Homma Y, et al. Silodosin, a new alpha1Aadrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men[J]. BJU Int, 2006, 98(5):10191024. [12] Moon K H, Song P H, Yang D Y, et al. Efficacy and safety of the selective α1A-Adrenoceptor blocker silodosin for severe lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, single-open-aabel, multicenter study in Korea[J]. Korean J Urol, 2014, 55(5): 335-340.

3. 毕业设计（论文）进程安排

2015.12.21-2016.1.4：论文选题，申报选题，查阅文献做好开题报告前准备； 2016.1.5-2016.1.15：完成外文翻译，文献综述和开题报告，网上提交； 2016.1.16-2016.2.22:修改完善实验方案，学习实验仪器操作； 2016.2.23-2016.4.4：完成项目方法学验证实验; 2016.4.5-2016.6.7: 分析实验数据，整理实验结果，完成毕业论文撰写。